SuperworthVerastem EPS VSTM
Diluted earnings per share by quarter and over the last twelve months, from 2011.
- Last 12 months, to Jun 30, 2026
- −$2.55
- Latest quarter, Q2 FY26
- −$0.35
- Fiscal year 2025
- −$3.32
Verastem's earnings per share was −$2.55 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.35.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$3.32 | n/a |
| FY2024 | −$3.50 | n/a |
| FY2023 | −$4.10 | n/a |
| FY2022 | −$4.56 | n/a |
| FY2021 | −$4.92 | n/a |
| FY2020 | −$6.36 | n/a |
| FY2019 | −$24.12 | n/a |
| FY2018 | −$16.44 | n/a |
| FY2017 | −$21.00 | n/a |
| FY2016 | −$11.76 | n/a |
| FY2015 | −$19.44 | n/a |
| FY2014 | −$24.84 | n/a |
| FY2013 | −$21.84 | n/a |
| FY2012 | −$20.52 | n/a |
| FY2011 | −$120.96 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.35 | n/a | −$2.55 | |
| Q1 FY26 | −$0.46 | n/a | −$2.82 | |
| Q4 FY25 | −$0.39 | n/a | −$3.32 | |
| Q3 FY25 | −$1.35 | n/a | −$4.26 | |
| Q2 FY25 | −$0.62 | n/a | −$3.51 | |
| Q1 FY25 | −$0.96 | n/a | −$3.20 | |
| Q4 FY24 | −$1.33 | n/a | −$3.50 | |
| Q3 FY24 | −$0.60 | n/a | −$3.19 | |
| Q2 FY24 | −$0.31 | n/a | −$3.34 | |
| Q1 FY24 | −$1.26 | n/a | −$4.40 | |
| Q4 FY23 | −$1.02 | n/a | −$4.10 | |
| Q3 FY23 | −$0.75 | n/a | −$4.04 |
Against its peers
Companies in Drug Manufacturers - General nearest Verastem's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| VSTMVerastem | −$2.55 | |
| ABUSArbutus Biopharma | $0.78 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| OMEROmeros | $1.52 | |
| CRMDCorMedix | $2.13 | +184% a year |
| ZVRAZevra Therapeutics | $0.93 | |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| PCRXPacira BioSciences | $0.35 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| ANABAnaptysbio | $4.57 | |
| Peer median | $1.08 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Verastem
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.